{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T20:17:27Z","timestamp":1788034647931,"version":"build-2784847793"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","award":["G-20-0028656"],"award-info":[{"award-number":["G-20-0028656"]}],"id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000028","name":"Institute of Circulatory and Respiratory Health","doi-asserted-by":"publisher","award":["PJT-198110"],"award-info":[{"award-number":["PJT-198110"]}],"id":[{"id":"10.13039\/501100000028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000028","name":"Institute of Circulatory and Respiratory Health","doi-asserted-by":"publisher","award":["PJT-175027"],"award-info":[{"award-number":["PJT-175027"]}],"id":[{"id":"10.13039\/501100000028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000028","name":"Institute of Circulatory and Respiratory Health","doi-asserted-by":"publisher","award":["123465"],"award-info":[{"award-number":["123465"]}],"id":[{"id":"10.13039\/501100000028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000028","name":"Institute of Circulatory and Respiratory Health","doi-asserted-by":"publisher","award":["PJT-173313"],"award-info":[{"award-number":["PJT-173313"]}],"id":[{"id":"10.13039\/501100000028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000191","name":"Kidney Foundation of Canada","doi-asserted-by":"publisher","award":["851937-21KHRG"],"award-info":[{"award-number":["851937-21KHRG"]}],"id":[{"id":"10.13039\/501100000191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000191","name":"Kidney Foundation of Canada","doi-asserted-by":"publisher","award":["24KHRG-1251453"],"award-info":[{"award-number":["24KHRG-1251453"]}],"id":[{"id":"10.13039\/501100000191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008582","name":"McGill University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020986","name":"Fondation de l'H\u00f4pital g\u00e9n\u00e9ral juif","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020986","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000023","name":"Government of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000023","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Quebec Health Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cjca.2026.08.004","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:08:45Z","timestamp":1787008125000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aldosterone in Hypertension: From Secondary Cause to Central Driver"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4502-2823","authenticated-orcid":false,"given":"Ernesto L.","family":"Schiffrin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Hundemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Goupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2026.08.004_bib1","doi-asserted-by":"crossref","first-page":"E549","DOI":"10.1503\/cmaj.241770","article-title":"Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care","volume":"197","author":"Goupil","year":"2025","journal-title":"CMAJ"},{"key":"10.1016\/j.cjca.2026.08.004_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-079108","article-title":"Diagnosis and management of resistant hypertension","volume":"385","author":"Schiffrin","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2026.08.004_bib3","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/ajh\/hpx064","article-title":"The potential role of primary care in case detection\/screening of primary aldosteronism","volume":"30","author":"Kline","year":"2017","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2026.08.004_bib4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2026.08.004_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/ajh\/hpaf156","article-title":"Rethinking primary aldosteronism: the 2025 John H. Laragh Research Award","volume":"39","author":"Hundemer","year":"2026","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2026.08.004_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.125.26401","article-title":"Resistant hypertension is not essential: it is primarily aldosteronism","volume":"83","author":"Brown","year":"2026","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2026.08.004_bib7","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.123.066389","article-title":"Subclinical primary aldosteronism and cardiovascular health: a population-based cohort study","volume":"149","author":"Hundemer","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.08.004_bib8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/CIRCULATIONAHA.124.073507","article-title":"Subclinical primary aldosteronism and major adverse cardiovascular events: a longitudinal population-based cohort study","volume":"152","author":"Goupil","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.08.004_bib9","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1161\/HYPERTENSIONAHA.107.103267","article-title":"Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients","volume":"51","author":"Savoia","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2026.08.004_bib10","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an endocrine society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cjca.2026.08.004_bib11","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2026.08.004_bib12","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.08.004_bib13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1126\/science.123.3195.503","article-title":"Human arterial hypertension: a state of mild chronic hyperaldosteronism?","volume":"123","author":"Genest","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.cjca.2026.08.004_bib14","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1001\/jamacardio.2018.2003","article-title":"Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism","volume":"3","author":"Hundemer","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2026.08.004_bib15","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/HYPERTENSIONAHA.117.10596","article-title":"Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term","volume":"71","author":"Rossi","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2026.08.004_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cjca.2026.08.004_bib17","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","article-title":"Renal outcomes in medically and surgically treated primary aldosteronism","volume":"72","author":"Hundemer","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2026.08.004_bib18","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1681\/ASN.0000001039","article-title":"Subclinical primary aldosteronism and eGFR decline over time","volume":"37","author":"Hundemer","year":"2026","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.cjca.2026.08.004_bib19","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.08.004_bib20","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1161\/HYPERTENSIONAHA.125.25104","article-title":"Adrenalectomy versus medical therapy in primary aldosteronism: a meta-analysis of long-term cardiac remodeling and function: Medical versus Adrenalectomy Treatment Compared in Hyperaldosteronism (MATCH) study","volume":"82","author":"Marzano","year":"2025","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2026.08.004_bib21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1146\/annurev-pharmtox-010716-104651","article-title":"GPER (GPR30): a nongenomic receptor (GPCR) for steroid hormones with implications for cardiovascular disease and cancer","volume":"57","author":"Feldman","year":"2017","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.cjca.2026.08.004_bib22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrneph.2010.30","article-title":"Aldosterone: effects on the kidney and cardiovascular system","volume":"6","author":"Briet","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.cjca.2026.08.004_bib23","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"SPRINT Research Group","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.08.004_bib24","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","article-title":"Final report of a trial of intensive versus standard blood-pressure control","volume":"384","author":"Lewis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.08.004_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11906-016-0628-7","article-title":"Role of inflammation and immunity in hypertension: recent epidemiological, laboratory, and clinical evidence","volume":"18","author":"Caillon","year":"2016","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.cjca.2026.08.004_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/01.HYP.0000078357.92682.EC","article-title":"Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling","volume":"42","author":"Pu","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2026.08.004_bib27","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1161\/CIRCRESAHA.109.196576","article-title":"Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors","volume":"105","author":"Lemari\u00e9","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2026.08.004_bib28","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.34067\/KID.0000000929","article-title":"Interplay between the mineralocorticoid system, inflammation, hypertension, and kidney disease","volume":"6","author":"Fields","year":"2025","journal-title":"Kidney360"},{"key":"10.1016\/j.cjca.2026.08.004_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-111167","article-title":"Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) - a clinical research protocol for a randomised controlled trial","volume":"15","author":"Merabtine","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.cjca.2026.08.004_bib30","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41371-024-00931-4","article-title":"A Randomized trial assessing Efficacy and safety of Mineralocorticoid receptor Antagonist therapy compared to Standard antihypertensive Therapy in hypErtension with low Renin (REMASTER): rationale and study design","volume":"38","author":"Shah","year":"2024","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.cjca.2026.08.004_bib31","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.08.004_bib32","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.08.004_bib33","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Lorundrostat efficacy and safety in patients with uncontrolled hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.08.004_bib34","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1053\/j.ajkd.2025.11.009","article-title":"Cumulative effects of vicadrostat and empagliflozin on albuminuria in CKD","volume":"87","author":"Rossing","year":"2026","journal-title":"Am J Kidney Dis"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X2601144X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X2601144X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T19:38:16Z","timestamp":1788032296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X2601144X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":34,"alternative-id":["S0828282X2601144X"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2026.08.004","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aldosterone in Hypertension: From Secondary Cause to Central Driver","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2026.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}